JPS6041619A - 分離用物質およびその製造方法 - Google Patents
分離用物質およびその製造方法Info
- Publication number
- JPS6041619A JPS6041619A JP59116324A JP11632484A JPS6041619A JP S6041619 A JPS6041619 A JP S6041619A JP 59116324 A JP59116324 A JP 59116324A JP 11632484 A JP11632484 A JP 11632484A JP S6041619 A JPS6041619 A JP S6041619A
- Authority
- JP
- Japan
- Prior art keywords
- separation
- stationary phase
- orosomucoid
- enantiomers
- enantiomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000926 separation method Methods 0.000 title claims description 27
- 239000000126 substance Substances 0.000 title claims description 21
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 230000005526 G1 to G0 transition Effects 0.000 claims description 29
- 102000012404 Orosomucoid Human genes 0.000 claims description 21
- 108010061952 Orosomucoid Proteins 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 13
- 150000002118 epoxides Chemical class 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- KHIWWQKSHDUIBK-UHFFFAOYSA-M periodate Chemical compound [O-]I(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-M 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- GMQPELBCDCDDHW-UHFFFAOYSA-N 4-(3,9-diazaspiro[5.5]undecan-3-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1N1CCC2(CCNCC2)CC1 GMQPELBCDCDDHW-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000000837 carbohydrate group Chemical group 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229960003869 mepenzolate bromide Drugs 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- 241001000171 Chira Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229960003150 bupivacaine Drugs 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- INWLQCZOYSRPNW-CYBMUJFWSA-N (2r)-n-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide Chemical compound CN1CCCC[C@@H]1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-CYBMUJFWSA-N 0.000 description 1
- INWLQCZOYSRPNW-ZDUSSCGKSA-N (2s)-n-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide Chemical compound CN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-ZDUSSCGKSA-N 0.000 description 1
- UVOIBTBFPOZKGP-CQSZACIVSA-N 1-[10-[(2r)-2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one Chemical compound C1=CC=C2N(C[C@@H](C)N(C)C)C3=CC(C(=O)CC)=CC=C3SC2=C1 UVOIBTBFPOZKGP-CQSZACIVSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101100166701 Arabidopsis thaliana CDKE-1 gene Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- DUDKAZCAISNGQN-UHFFFAOYSA-N Oxyphencyclimine Chemical compound CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 DUDKAZCAISNGQN-UHFFFAOYSA-N 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000219781 Pueraria montana var. lobata Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- 229960002369 oxyphencyclimine Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960005036 propiomazine Drugs 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8303221-9 | 1983-06-08 | ||
| SE8303221A SE445649B (sv) | 1983-06-08 | 1983-06-08 | Anvendning av en fast berare med immobiliserad orosomucoid for separation, forfarande for framstellning av separationsmaterial, separationsanordning samt separationsmaterial |
| SE8307023-5 | 1983-12-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6041619A true JPS6041619A (ja) | 1985-03-05 |
| JPH0213648B2 JPH0213648B2 (enExample) | 1990-04-04 |
Family
ID=20351491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59116324A Granted JPS6041619A (ja) | 1983-06-08 | 1984-06-05 | 分離用物質およびその製造方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6041619A (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61157698U (enExample) * | 1985-03-25 | 1986-09-30 | ||
| WO1993007104A1 (en) * | 1991-10-09 | 1993-04-15 | Eisai Co., Ltd. | Separating agent comprising bonded conalbumin |
| JP2015064330A (ja) * | 2013-08-29 | 2015-04-09 | 株式会社ダイセル | 光学異性体用分離剤 |
| WO2015122031A1 (ja) * | 2014-02-17 | 2015-08-20 | 株式会社Ｌｔｔバイオファーマ | メペンゾラート光学活性体及びそれを有効成分とする慢性閉塞性肺疾患改善剤 |
-
1984
- 1984-06-05 JP JP59116324A patent/JPS6041619A/ja active Granted
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61157698U (enExample) * | 1985-03-25 | 1986-09-30 | ||
| WO1993007104A1 (en) * | 1991-10-09 | 1993-04-15 | Eisai Co., Ltd. | Separating agent comprising bonded conalbumin |
| US5900144A (en) * | 1991-10-09 | 1999-05-04 | Eisai Co., Ltd. | Separating agent comprising bonded conalbumin |
| JP2015064330A (ja) * | 2013-08-29 | 2015-04-09 | 株式会社ダイセル | 光学異性体用分離剤 |
| WO2015122031A1 (ja) * | 2014-02-17 | 2015-08-20 | 株式会社Ｌｔｔバイオファーマ | メペンゾラート光学活性体及びそれを有効成分とする慢性閉塞性肺疾患改善剤 |
| JPWO2015122031A1 (ja) * | 2014-02-17 | 2017-03-30 | 株式会社Ｌｔｔバイオファーマ | メペンゾラート光学活性体及びそれを有効成分とする慢性閉塞性肺疾患改善剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0213648B2 (enExample) | 1990-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4612121A (en) | Separation material, methods of producing a separation material and use of orosomucoid, functional analogs thereto or derivatives or fragments thereof for separation purposes | |
| US4245005A (en) | Pellicular coated support and method | |
| Fornstedt et al. | Thermodynamic study of an unusual chiral separation. Propranolol enantiomers on an immobilized cellulase | |
| Nishi et al. | Optical resolution of drugs by capillary electrophoretic techniques | |
| CA1320718C (en) | Chromatographic material | |
| JP3808500B2 (ja) | 分離剤としての大環状抗生物質 | |
| EP0240013B1 (en) | Separation agent for optical isomers, process for preparing it and use thereof | |
| Haginaka et al. | . beta.-Cyclodextrin-bonded silica for direct injection analysis of drug enantiomers in serum by liquid chromatography | |
| Mohammad et al. | Chiral‐recognition chromatography of β‐blockers on continuous polymer beds with immobilized cellulase as enantioselective protein | |
| US5135649A (en) | Column packing material with both hydrophobic and hydrophilic groups and process for production thereof | |
| EP0153763B1 (en) | Affinity chromatography matrix with built-in reaction indicator | |
| Stalcup et al. | Determination of enantiomers in human serum by direct injection onto a β-cyclodextrin HPLC bonded phase | |
| JPS6041619A (ja) | 分離用物質およびその製造方法 | |
| Ernst-Cabrera et al. | High-performance affinity chromatography | |
| Kuroda et al. | Role of biantennary glycans and genetic variants of human α1-acid glycoprotein in enantioselective binding of basic drugs as studied by high performance frontal analysis/capillary electrophoresis | |
| JP2947924B2 (ja) | 光学異性体用分離剤 | |
| Narayanan et al. | “Glutaraldehyde-P”, a stable, reactive aldehyde matrix for affinity chromatography | |
| JPH0797108B2 (ja) | アフィニティークロマトグラフィー用のポリエチレンイミンマトリックス | |
| JP2818857B2 (ja) | クロマトグラフィー用充填剤の製造方法 | |
| JPH01123145A (ja) | カラム用充填剤及びその製造方法 | |
| JPH0764541B2 (ja) | 内面疎水型シリカゲルの製造方法 | |
| JP3219296B2 (ja) | カラム充填剤及びその製造方法 | |
| US7575908B1 (en) | Immobilization method for producing active α1-acid glycoprotein | |
| JP2506633B2 (ja) | 環状カルボニル化合物の光学分割方法 | |
| JPH0767692A (ja) | 光学異性体用分離剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |